Skip to main content

Research Repository

Advanced Search

Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma

Beasley, Richard; Holliday, Mark; Reddel, Helen K.; Braithwaite, Irene; Ebmeier, Stefan; Hancox, Robert J.; Harrison, Tim; Houghton, Claire; Oldfield, Karen; Papi, Alberto; Pavord, Ian D.; Williams, Mathew; Weatherall, Mark

Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma Thumbnail


Authors

Richard Beasley

Mark Holliday

Helen K. Reddel

Irene Braithwaite

Stefan Ebmeier

Robert J. Hancox

TIM HARRISON tim.harrison@nottingham.ac.uk
Professor of Asthma and Respiratory Medicine

Claire Houghton

Karen Oldfield

Alberto Papi

Ian D. Pavord

Mathew Williams

Mark Weatherall



Abstract

BACKGROUND
In double-blind, placebo-controlled trials, budesonide–formoterol used on an as-needed basis resulted in a lower risk of severe exacerbation of asthma than as-needed use of a short-acting β2-agonist (SABA); the risk was similar to that of budesonide maintenance therapy plus as-needed SABA. The availability of data from clinical trials designed to better reflect clinical practice would be beneficial.

METHODS
We conducted a 52-week, randomized, open-label, parallel-group, controlled trial involving adults with mild asthma. Patients were randomly assigned to one of three treatment groups: albuterol (100 μg, two inhalations from a pressurized metered-dose inhaler as needed for asthma symptoms) (albuterol group); budesonide (200 μg, one inhalation through a Turbuhaler twice daily) plus as-needed albuterol (budesonide maintenance group); or budesonide–formoterol (200 μg of budesonide and 6 μg of formoterol, one inhalation through a Turbuhaler as needed) (budesonide–formoterol group). Electronic monitoring of inhalers was used to measure medication use. The primary outcome was the annualized rate of asthma exacerbations.

RESULTS
The analysis included 668 of 675 patients who underwent randomization. The annualized exacerbation rate in the budesonide–formoterol group was lower than that in the albuterol group (absolute rate, 0.195 vs. 0.400; relative rate, 0.49; 95% confidence interval [CI], 0.33 to 0.72; P

Citation

Beasley, R., Holliday, M., Reddel, H. K., Braithwaite, I., Ebmeier, S., Hancox, R. J., …Weatherall, M. (2019). Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma. New England Journal of Medicine, 380(21), 1-11. https://doi.org/10.1056/nejmoa1901963

Journal Article Type Article
Acceptance Date Apr 19, 2019
Online Publication Date May 19, 2019
Publication Date May 23, 2019
Deposit Date Jun 19, 2019
Publicly Available Date Nov 20, 2019
Journal New England Journal of Medicine
Print ISSN 0028-4793
Electronic ISSN 1533-4406
Publisher Massachusetts Medical Society
Peer Reviewed Peer Reviewed
Volume 380
Issue 21
Pages 1-11
DOI https://doi.org/10.1056/nejmoa1901963
Keywords General Medicine
Public URL https://nottingham-repository.worktribe.com/output/2208247
Publisher URL https://www.nejm.org/doi/full/10.1056/NEJMoa1901963
Contract Date Jun 19, 2019

Files

Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma (385 Kb)
PDF





You might also like



Downloadable Citations